Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	6/14/2002 9:08:04 AM
From: nigel bates	of 625

First Phase III Data for Abbott Laboratories' D2E7 (Adalimumab) Support Promise in Rheumatoid Arthritis (RA) -- Results Presented at European Rheumatology Meeting Suggest Safety and Durability of Response in RA -- Message 17602486 Elsewhere - ...The only adverse events that differed significantly between D2E7 and placebo were injection site reactions, rash and back pain, the company said. "What you see here is one of the largest safety trials," Rebecca Hoffman, associate medical director at Abbott, said in an interview. "It mimicked natural practice for rheumatologists, so patients could be on any DMARD when they came into the trial." Rheumatologists have expressed concern recently that even the latest Cox-2 inhibitors -- while much safer on the stomach than traditional aspirin-like anti-inflammatory drugs -- might be linked with increased risk of heart and kidney problems. Hoffman said all adverse events, including severe or life-threatening ones, were considered in the trials of D2E7. Overall, the percentage of adverse events was 86.5 percent in the drug group compared with 82.7 percent in the placebo arm...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next